# Is the BIOS-Rank panel *useful*? — criteria checklist

**Distinction:** Statistical significance (adj.*P* / huge DEG lists) ≠ clinical/biological utility.  
BIOS-Rank targets **utility**: platform-invariant, biologically coherent, compact, and better than chance.

**Verdict overall:** **Yes — useful by all four criteria on the evidence below** (with honest caveats in the Notes column).

---

## Master table

| # | Utility criterion | “Useful” marker (your definition) | BIOS-Rank evidence | vs limma / ∩ / random | Pass? |
|---|-------------------|-----------------------------------|--------------------|------------------------|:-----:|
| **1** | **Platform invariance** | Works on microarray **and** RNA-seq; not a platform artifact (\(E_p\), \(E_x\)) | D1 top-20: med AUC micro **0.942**, RNA **0.937**, min-median **0.924** (balanced) | Limma/∩: micro **0.966** but RNA **0.884** (assay-skewed); min-median **0.884**; random **0.807**. D3: BIOS **0.946** = limma, ≫ random **0.781** | **PASS** |
| **2** | **Biological fidelity** | In disease co-expression programmes / multi-selector stable (\(E_m\), \(E_s\)); not batch-only significance | D1 BIOS panel: **100%** trait-WGCNA (\(E_m\)); **80%** ML/consensus (\(E_s\)); mean Ep ≈ **1.0** | Limma top-20: Em **40%**, Es **10%**. ONLY_Ex (AUC-chasing): Es only **20%**. Unfiltered DE ≈ **7051** genes | **PASS** |
| **3** | **Clinical compactness** | Top-20 actionable (qPCR / targeted panel), not thousands of DEGs | Soft BIOS panel ***k* = 20**; hard consensus ***k* ≈ 19–20** | Unfiltered limma DEGs **~7051**; matched-*k* limma can match AUC but without biology filters | **PASS** |
| **4** | **Null / calibration** | Better than chance; composite score above label-shuffle null (BIOS-FDR) | BIOS-FDR top-20: empirical FDR **0.0015**; mean BIOS **0.907** vs null **0.631**; emp. *P* **0.0099**. Gene AUC ≫ random on D1–D3 | Random matched-*k*: D1 **0.807**, D2 **0.67**, D3 **0.781**. Limma also highly specific at extreme adj.*P* — do **not** claim “better FDR than limma”; claim **calibrated multi-channel enrichment** | **PASS** |

---

## Your four named tests → mapped to results

| Your test | Components | What “fail” looks like | What you observed |
|-----------|------------|------------------------|-------------------|
| Platform invariance | \(E_p\), \(E_x\) | High micro AUC, collapses on RNA (or vice versa) | BIOS balanced 0.942/0.937; limma skewed 0.966→0.884 |
| Biological fidelity | \(E_m\), \(E_s\) | Significant but not in disease modules / unstable selectors | BIOS 100% WGCNA, 80% ML; limma 42%/11% |
| Clinical compactness | Top-*k* | 1000s of DEGs as “biomarkers” | *k*=20 vs ~7051 DEGs |
| Null hypothesis (calibration) | BIOS-FDR + random panel | Same as shuffled labels / random genes | FDR 0.0015; *P*=0.0099; always ≫ random |

---

## Specificity across cohorts (extra row you listed under “Specificity”)

| Cohort | Metric | BIOS | Baseline | Random | Useful? |
|--------|--------|-----:|---------:|-------:|:-------:|
| D1 GSE89076 × GSE50760 | min-median cross-assay | **0.924** | 0.884 (limma/∩) | 0.807 | **Yes (beats limma)** |
| D2 GSE50760 → GSE104836 | external median gene AUC | 0.980 | 0.980 (limma) | 0.670 | **Yes (tie; ≫ random)** |
| D3 GSE9348 × GSE50760 | min-median cross-assay | 0.946 | 0.946 (limma) | 0.781 | **Yes (tie; ≫ random)** |

---

## Caveats (say these out loud to peers)

1. **Useful ≠ clinically validated.** You show *translational readiness criteria* (compact, cross-assay, biology, non-random)—not a hospital-approved diagnostic.  
2. **D2/D3 ceiling:** matching limma at AUC ~0.95–0.98 is still useful if you also pass biology + compactness; do not oversell “always beats limma.”  
3. **BIOS-FDR** proves the *composite score* is enriched vs shuffled Condition—not that every gene is a drug target.  
4. **CRC-focused** real data; simulation supports the joint estimand more generally.

---

## One-sentence answer for a committee

> A BIOS-Rank top-20 panel is **useful** in the sense that it is **platform-balanced**, **module/ML-coherent**, **compact enough for targeted assays**, and **significantly better than chance**—whereas standard DEG lists are often significant yet assay-skewed, huge, and weakly constrained by biology.

**Does significance vs utility align with your framework?** **Yes.** Your four tests are exactly how BIOS operationalizes utility; the table above shows all four are met on current evidence.
